1. Home
  2. RDI vs FEMY Comparison

RDI vs FEMY Comparison

Compare RDI & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDI

Reading International Inc

HOLD

Current Price

$1.06

Market Cap

25.7M

ML Signal

HOLD

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.41

Market Cap

23.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
FEMY
Founded
1937
2004
Country
United States
United States
Employees
2005
N/A
Industry
Movies/Entertainment
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.7M
23.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RDI
FEMY
Price
$1.06
$0.41
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.50
AVG Volume (30 Days)
18.2K
381.8K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
44.71
EPS
N/A
N/A
Revenue
N/A
$2,293,313.00
Revenue This Year
$16.25
$105.16
Revenue Next Year
$4.04
$200.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
40.77
52 Week Low
$0.94
$0.31
52 Week High
$1.65
$1.11

Technical Indicators

Market Signals
Indicator
RDI
FEMY
Relative Strength Index (RSI) 39.67 45.84
Support Level $0.99 $0.33
Resistance Level $1.16 $0.44
Average True Range (ATR) 0.05 0.04
MACD -0.01 0.01
Stochastic Oscillator 15.80 41.60

Price Performance

Historical Comparison
RDI
FEMY

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: